'Oral isotretinoin plus desloratadine for acne vulgaris: an updated global meta-analysis of efficacy, safety, and patient-centered outcomes'.
Mishari Tariq Alrubaiaan, Reem Bajamaan, Alwaleed Mohammed Altuwaijri et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis assessed oral isotretinoin plus desloratadine versus isotretinoin alone for acne vulgaris, pooling nine clinical trials involving 608 patients. Combination therapy was associated with lower Global Acne Grading System (GAGS) scores at each reported assessment, from 4 to 24 weeks. At 12 weeks, the mean difference was -3.62 (95% CI: -4.98 to -2.26; p < 0.00001). The combination also increased the odds of clinical efficacy, defined as greater than 90% GAGS reduction, and was associated with fewer flare-ups and less pruritus; laboratory safety parameters did not change significantly.
Key findings
- At 12 weeks, GAGS scores were lower with combination therapy (MD: -3.62; 95% CI: -4.98 to -2.26; p < 0.00001).
- Clinical efficacy (>90% GAGS reduction) was more likely with combination therapy (OR: 2.39; 95% CI: 1.19 to 4.78; p = 0.01).
- Combination therapy was associated with fewer flare-ups (OR: 0.38; p = 0.009) and less pruritus (OR: 0.13; p < 0.00001).
- Patient satisfaction was greater, with no significant changes in laboratory safety parameters.
Why it matters
The pooled findings suggest that adding desloratadine may improve acne severity outcomes and reduce flare-ups and pruritus during isotretinoin treatment, while laboratory safety measures remained unchanged. These outcomes are relevant to treatment tolerability and patient experience, although the results should be interpreted in light of the evidence base and do not establish that the combination is appropriate for every patient.
What to keep in mind
The meta-analysis included nine clinical trials; the abstract does not report further details on trial quality, heterogeneity, or follow-up beyond the stated assessment times.